Clinical Trials Transformation Initiative (CTTI)
Antibacterial Drug Development Working Group Webinar
Thursday August 29, 2013

Patrick Ajiboye Quintiles
Paul Ambrose Institute for Clinical Pharmacodynamics
Steven Barriere Theravance
Kimberly Bergman FDA
Robert Bonomo Louis Stokes Cleveland VA Medical Center
Robert Califf Duke University Medical Center
Gregory Campbell FDA
Daniel Chertow NIH
Deborah Collyar Patient Advocates in Research
Heather Colvin The Brookings Institute
Carrie Dombeck Duke University Medical Center
Sabrina Comic-Savic The Medicines Co.
Edward Cox FDA
Heather Cross Duke University Medical Center
Aaron Dane AstraZeneca
Robert Danner NIH
Anita Das AxiStat
Helen Donnelly Northwestern University Feinberg School of Medicine
Mike Dudley Rempex Pharma
Barry Eisenstein Cubist
John Farley FDA
Thomas File Summa Health System
Thomas Fleming University of Washington
Vance Fowler Duke University Medical Center
David Friedland Cerexa
Ian Friedland Cubist
Margaret Gamalo FDA
Christine Ginocchio North Shore-LIJ Health System
Robert Guidos FDA
Peter Hoffmann Duke University Medical Center
Steve Hoffmann FNIH
Mohammad Huque FDA
Dmitri Iarikov FDA
Andre Kalil University of Nebraska
Charles Knirsch Pfizer
Marin Kollef University of Washington
Sarrit Kovacs FDA
Judith Kramer Clinical Trials Transformation Initiative
Clinical Trials Transformation Initiative (CTTI)
Antibacterial Drug Development Working Group Webinar
Thursday August 29, 2013

Mark Kunkel          Pfizer
Lisa LaVange         FDA
Katherine Laessig    FDA
Daphne Lin           FDA
Benjamin Lorenz      FDA
Debra Marion         Duke University Medical Center
Kunal Merchant       Clinical Trials Transformation Initiative
Matthew Metz         FDA
Sumathi Nambiar      FDA
Lena Napolitano      University of Michigan
Eileen Navarro Almario FDA
Gary Noel            AstraZeneca
Naomi O'Grady        NIH
John Powers          NIH/George Washington University School of Medicine
Dionne Price         FDA
Phillipe Prokocimer  Trius Therapeutics, Inc.
Rebecca Redman       Johnson & Johnson
John Rex             AstraZeneca
David Roeder         FDA
Daniel Rubin         FDA
Marcus Ruopp         Duke University Medical Center
Leonard Sacks        FDA
Jonas Santiago        FDA
David Shales         Anti-infectives Consulting
Rachel Sherman       FDA
Judy Siuciak         ASPET
Ashley Slagle        FDA
Thomas D. Smith      FDA
Brad Spellberg       UCLA Medical Center
George Talbot        Talbot Advisors LLC
Rose Tiernan         FDA
Pamela Tenaerts      Clinical Trials Transformation Initiative
Joseph Toerner       FDA
John Tomayko         GlaxoSmithKline
Ephraim Tsalik       Duke University Medical Center
Thamban Valappil     FDA
Richard Wunderink    Northwestern University Feinberg School of Medicine
Grace Yan            FDA